Literature DB >> 29194012

Funding vaccines for emerging infectious diseases.

Gary Wong1, Xiangguo Qiu2,3.   

Abstract

Immunization has played a large role in substantially reducing the infected and death tolls from infectious diseases. In the case of emerging diseases, the identity of the pathogen responsible, as well as the time and location for the next outbreak, cannot be accurately predicted using current means. Coupled with disjointed efforts towards the development of vaccines and a lack of funds and desire to advance promising products against known emerging pathogens to clinical trials, there has been a shortage of approved products ready for emergency use. Recent outbreaks have exposed these weaknesses, and the Coalition for Epidemic Preparedness Innovations (CEPI) was created in 2016 to address these issues. In this commentary, we discuss the establishment of such a global vaccine fund, and provide some additional points to consider for stimulating further discussion on this comprehensive, ambitious initiative.

Entities:  

Keywords:  Ebola; MERS; SARS; Zika; funding; influenza; vaccine; vaccinology

Mesh:

Substances:

Year:  2018        PMID: 29194012      PMCID: PMC6067896          DOI: 10.1080/21645515.2017.1412024

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  8 in total

1.  A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Authors:  J E Ledgerwood; P Costner; N Desai; L Holman; M E Enama; G Yamshchikov; S Mulangu; Z Hu; C A Andrews; R A Sheets; R A Koup; M Roederer; R Bailer; J R Mascola; M G Pau; N J Sullivan; J Goudsmit; G J Nabel; B S Graham
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

Review 2.  The gold industry standard for risk and cost of drug and vaccine development revisited.

Authors:  E S Pronker; T C Weenen; H R Commandeur; A D M E Osterhaus; H J H M Claassen
Journal:  Vaccine       Date:  2011-06-29       Impact factor: 3.641

3.  Establishing a Global Vaccine-Development Fund.

Authors:  Stanley A Plotkin; Adel A F Mahmoud; Jeremy Farrar
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

4.  New Vaccines against Epidemic Infectious Diseases.

Authors:  John-Arne Røttingen; Dimitrios Gouglas; Mark Feinberg; Stanley Plotkin; Krishnaswamy V Raghavan; Andrew Witty; Ruxandra Draghia-Akli; Paul Stoffels; Peter Piot
Journal:  N Engl J Med       Date:  2017-01-18       Impact factor: 91.245

5.  Genesis, Evolution and Prevalence of H5N6 Avian Influenza Viruses in China.

Authors:  Yuhai Bi; Quanjiao Chen; Qianli Wang; Jianjun Chen; Tao Jin; Gary Wong; Chuansong Quan; Jun Liu; Jun Wu; Renfu Yin; Lihua Zhao; Mingxin Li; Zhuang Ding; Rongrong Zou; Wen Xu; Hong Li; Huijun Wang; Kegong Tian; Guanghua Fu; Yu Huang; Alexander Shestopalov; Shoujun Li; Bing Xu; Hongjie Yu; Tingrong Luo; Lin Lu; Xun Xu; Yang Luo; Yingxia Liu; Weifeng Shi; Di Liu; George Fu Gao
Journal:  Cell Host Microbe       Date:  2016-12-01       Impact factor: 21.023

6.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Authors:  Steven M Jones; Heinz Feldmann; Ute Ströher; Joan B Geisbert; Lisa Fernando; Allen Grolla; Hans-Dieter Klenk; Nancy J Sullivan; Viktor E Volchkov; Elizabeth A Fritz; Kathleen M Daddario; Lisa E Hensley; Peter B Jahrling; Thomas W Geisbert
Journal:  Nat Med       Date:  2005-06-05       Impact factor: 53.440

7.  Role for migratory wild birds in the global spread of avian influenza H5N8.

Authors: 
Journal:  Science       Date:  2016-10-14       Impact factor: 47.728

8.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.

Authors:  Nancy J Sullivan; Thomas W Geisbert; Joan B Geisbert; Ling Xu; Zhi-Yong Yang; Mario Roederer; Richard A Koup; Peter B Jahrling; Gary J Nabel
Journal:  Nature       Date:  2003-08-07       Impact factor: 49.962

  8 in total
  7 in total

1.  Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases.

Authors:  Ziyang Xu; Michelle Ho; Devivasha Bordoloi; Sagar Kudchodkar; Makan Khoshnejad; Leila Giron; Faraz Zaidi; Moonsup Jeong; Christine C Roberts; Young K Park; Joel Maslow; Mohamed Abdel-Mohsen; Kar Muthumani
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development.

Authors:  Giovanni Rezza; Scott C Weaver
Journal:  PLoS Negl Trop Dis       Date:  2019-01-17

Review 3.  Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development.

Authors:  Christine C Roberts
Journal:  Hum Vaccin Immunother       Date:  2019-07-16       Impact factor: 3.452

Review 4.  Developing vaccines against epidemic-prone emerging infectious diseases.

Authors:  Valentina Bernasconi; Paul A Kristiansen; Mike Whelan; Raúl Gómez Román; Alison Bettis; Solomon Abebe Yimer; Céline Gurry; Svein R Andersen; Debra Yeskey; Henshaw Mandi; Arun Kumar; Johan Holst; Carolyn Clark; Jakob P Cramer; John-Arne Røttingen; Richard Hatchett; Melanie Saville; Gunnstein Norheim
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-01       Impact factor: 1.513

5.  A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.

Authors:  Patricio Oyarzun; Manju Kashyap; Victor Fica; Alexis Salas-Burgos; Faviel F Gonzalez-Galarza; Antony McCabe; Andrew R Jones; Derek Middleton; Bostjan Kobe
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 6.  Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies.

Authors:  Jung-Ah Choi; Jae-Ouk Kim
Journal:  J Microbiol       Date:  2022-01-28       Impact factor: 2.902

Review 7.  Ganoderma lucidum: Unutilized natural medicine and promising future solution to emerging diseases in Africa.

Authors:  M A Oke; F J Afolabi; O O Oyeleke; T A Kilani; A R Adeosun; A A Olanbiwoninu; E A Adebayo
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.